Updated Jul 16, 2026
BONNEY MICHAEL W has filed 2 SEC Form 4 filings across 2 companies in the last 90 days — selling. Lifetime open-market sales: $8.19M.
Michael W. Bonney is a director at Alnylam Pharmaceuticals, a company specializing in RNA interference therapeutics. He has held various roles in the pharmaceutical industry and is known for his contributions to drug development and corporate governance.
| Role | Director |
|---|---|
| Notability | 50/100 |
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2025-08-18 | ALNY | ALNYLAM PHARMACEUTICALS, INC. | S — Open-market sale | 11.2K | $450.00 | $5.06M |
| 2025-08-18 | ALNY | ALNYLAM PHARMACEUTICALS, INC. | M — Option exercise | 11.2K | $70.20 | $790K |
| 2025-05-15 | ALNY | ALNYLAM PHARMACEUTICALS, INC. | S — Open-market sale | 1.6K | $283.83 | $459K |
| 2025-05-15 | ALNY | ALNYLAM PHARMACEUTICALS, INC. | S — Open-market sale | 1.7K | $282.81 | $489K |
| 2025-05-15 | ALNY | ALNYLAM PHARMACEUTICALS, INC. | S — Open-market sale | 802 | $282.03 | $226K |
| 2025-05-15 | ALNY | ALNYLAM PHARMACEUTICALS, INC. | S — Open-market sale | 372 | $281.10 | $105K |
| 2025-05-15 | ALNY | ALNYLAM PHARMACEUTICALS, INC. | S — Open-market sale | 432 | $280.03 | $121K |
| 2025-05-15 | ALNY | ALNYLAM PHARMACEUTICALS, INC. | S — Open-market sale | 1.2K | $278.01 | $344K |
| 2025-05-15 | ALNY | ALNYLAM PHARMACEUTICALS, INC. | S — Open-market sale | 1.3K | $277.16 | $350K |
| 2025-05-15 | ALNY | ALNYLAM PHARMACEUTICALS, INC. | S — Open-market sale | 301 | $275.63 | $83K |
| 2025-05-15 | ALNY | ALNYLAM PHARMACEUTICALS, INC. | S — Open-market sale | 882 | $273.75 | $241K |
| 2025-05-15 | ALNY | ALNYLAM PHARMACEUTICALS, INC. | S — Open-market sale | 660 | $273.16 | $180K |
| 2025-05-15 | ALNY | ALNYLAM PHARMACEUTICALS, INC. | S — Open-market sale | 431 | $271.68 | $117K |
| 2025-05-15 | ALNY | ALNYLAM PHARMACEUTICALS, INC. | S — Open-market sale | 245 | $269.79 | $66K |
| 2025-05-15 | ALNY | ALNYLAM PHARMACEUTICALS, INC. | S — Open-market sale | 729 | $268.56 | $196K |
| 2025-05-15 | ALNY | ALNYLAM PHARMACEUTICALS, INC. | S — Open-market sale | 549 | $267.14 | $147K |
| 2025-05-15 | ALNY | ALNYLAM PHARMACEUTICALS, INC. | M — Option exercise | 11.2K | $131.21 | $1.48M |
| 2025-05-08 | ALNY | ALNYLAM PHARMACEUTICALS, INC. | A — Grant or award | 775 | $0.00 |
Michael W. Bonney is a director at Alnylam Pharmaceuticals, a company specializing in RNA interference therapeutics. He has held various roles in the pharmaceutical industry and is known for his contributions to drug development and corporate governance.…
2 primary Form 4 filings in the last 90 days, covering 2 companies.
Recorded transactions: 0 open-market purchases () and 15 open-market sales ($8.19M) across all tracked filings.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live BONNEY MICHAEL W profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.